Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: An international prospective study (INTERCOM)

American Journal of Transplantation

Volumn 13, Issue 11, 2013, Pages 2865-2874

  Halloran, P F ^a,b   Pereira, A B ^a,c   Chang, J ^a   Matas, A ^d   Picton, M ^e   De Freitas, D ^e   Bromberg, J ^f   Seron D ^g   Sellares J ^g   Einecke, G ^h   Reeve, J ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c University of Minnesota ^*  (Brazil)

^d UNIVERSITY OF MINNESOTA   (United States)

^e MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antibody mediated rejection; classifier; kidney transplant; microarrays; molecular diagnostics

Indexed keywords

HLA ANTIBODY;

ADULT; ANTIBODY MEDIATED REJECTION; ANTIBODY MEDIATED REJECTION SCORE; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; GRAFT FAILURE; GRAFT SURVIVAL; HISTOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; VALIDATION STUDY;

ANTIBODY-MEDIATED REJECTION; CLASSIFIER; KIDNEY TRANSPLANT; MICROARRAYS; MOLECULAR DIAGNOSTICS;

ADOLESCENT; BIOLOGICAL MARKERS; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INTERNATIONAL AGENCIES; ISOANTIBODIES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84886800383     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12465     Document Type: Article

References (34)

1. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
2. Sellares J, De Freitas D, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and non-adherence. Am J Transplant 2012; 12: 388-399.
3. Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated vascular rejection of kidney allografts: A population-based study. Lancet 2013; 381: 313-319.
4. Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS., The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplant 1990; 49: 85-91.
5. Feucht HE, Felber E, Gokel MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86: 464-470.
6. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760.
7. Furness PN, Taub N, Assmann KJ, et al. International variation in histologic grading is large, and persistent feedback does not improve reproducibility. Am J Surg Pathol 2003; 27: 805-810.
8. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168-1179.
9. Seemayer CA, Gaspert A, Nickeleit V, Mihatsch MJ., C4d staining of renal allograft biopsies: A comparative analysis of different staining techniques. Nephrol Dial Transplant 2007; 22: 568-576.
10. Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 2011; 11: 896-906.
11. Mengel M, Sis B, Haas M, et al. Banff 2011 meeting report: New concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563-570.
12. Rutjes AW, Reitsma JB, Coomarasamy A, Khan KS, Bossuyt PM., Evaluation of diagnostic tests when there is no gold standard. A review of methods. Health Technol Assess 2007; 11: ix-51.
13. Limmathurotsakul D, Turner EL, Wuthiekanun V, et al. Fool's gold: Why imperfect reference tests are undermining the evaluation of novel diagnostics: A reevaluation of 5 diagnostic tests for leptospirosis. Clin Infect Dis 2012; 55: 322-331.
14. Sellares J, Reeve J, Loupy A, et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant 2013; 13: 971-983.
15. Hidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: Evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010; 10: 1812-1822.
16. Hidalgo LG, Sellares J, Sis B, Mengel M, Chang J, Halloran PF., Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. Am J Transplant 2012; 12: 1180-1191.
17. Halloran PF, Pereira A, Chang J, et al. Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: The INTERCOM study. Am J Transplant 2013; 13: 2352-2363.
18. Luo J, Schumacher M, Scherer A, et al. A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics 2012; 10: 278-291.
19. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2013. Available at: http://www.R-project.org/. Accessed September 11, 2013.
20. Pencina MJ, D'Agostino RB Sr., Steyerberg EW., Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30: 11-21.
21. Baid-Agrawal S, Farris AB III, Pascual M, et al. Overlapping pathways to transplant glomerulopathy: Chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int 2011; 80: 879-885.
22. Reitsma JB, Rutjes AW, Khan KS, Coomarasamy A, Bossuyt PM., A review of solutions for diagnostic accuracy studies with an imperfect or missing Reference Standard. J Clin Epidemiol 2009; 62: 797-806.
23. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547-557.
24. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
25. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575.
26. Alachkar N, Gupta G, Montgomery RA., Angiotensin antibodies and focal segmental glomerulosclerosis. N Engl J Med 2013; 368: 971-973.
27. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558-569.
28. Prat A, Parker JS, Fan C, et al. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol 2012; 23: 2866-2873.
29. Hartmann S, Gerber B, Elling D, Heintze K, Reimer T., The 70-gene signature as prognostic factor for elderly women with hormone receptor-positive, HER2-Negative Breast Cancer. Breast Care (Basel) 2012; 7: 19-24.
30. Yang M, Rajan S, Issa AM., Cost effectiveness of gene expression profiling for early stage breast cancer: A decision-analytic model. Cancer 2012; 118: 6298-6299.
31. Mirnezami R, Nicholson J, Darzi A., Preparing for precision medicine. N Engl J Med 2012; 366: 489-491.
32. Reeve J, Sellares J, Mengel M, et al. Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am J Transplant 2013; 13: 645-655.
33. Famulski KS, de Freitas DG, Kreepala C, et al. Molecular phenotypes of acute kidney injury in human kidney transplants. JASN 2012; 23: 948-958.
34. Einecke G, Reeve J, Sis B, et al. A molecular classifier for predicting future graft loss in late kidney transplant biopsies. J Clin Invest 2010; 120: 1862-1872.